Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Mississippi: - Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Mississippi: - Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
- Baptist Cancer Center-Grenada — Grenada, Mississippi
- Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
- Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
- Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Mississippi: - Jackson Oncology Associates - The Hederman Cancer Center — Jackson, Mississippi
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Mississippi: - North Mississippi Hematology and Oncology Associates — Tupelo, Mississippi
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Mississippi: - Clinical Study Site — Hattiesburg, Mississippi
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Mississippi: - Research Site — Hattiesburg, Mississippi
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Mississippi: - Hattiesburg Clinic Hematology/Oncology — Hattiesburg, Mississippi
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Mississippi: - Hattiesburg Clinic Hematology/Oncology — Hattiesburg, Mississippi
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Mississippi: - Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
- Baptist Cancer Center-Grenada — Grenada, Mississippi
- University of Mississippi Medical Center — Jackson, Mississippi
- Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
- Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Recruiting Academic/Other
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Sm…
Sponsor: PrECOG, LLC.
NCT ID: NCT06538038
Sites in Mississippi: - Baptist Memorial Hospital and Cancer Center - Golden Triangle — Columbus, Mississippi
- Baptist Cancer Center - Grenada — Grenada, Mississippi
- Jackson Oncology Associates PLLC — Jackson, Mississippi
- Mississippi Baptist Medical Center — Jackson, Mississippi
- Baptist Memorial Hospital and Cancer Center - Union — New Albany, Mississippi
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Mississippi: - Massive Bio SYNERGY-AI site — Hattiesburg, Mississippi
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in Mississippi: - Memorial Hospital at Gulfport — Gulfport, Mississippi